What question did this study set out to answer?

To evaluate the effects of regular short-acting β2-agonist (SABA) use over two weeks on diurnal variation and tolerance during home peak expiratory flow (PEF) monitoring.

April 18, 2026Heart & Lung0 citationsOpen Access

View Full Paper

Regular short-acting β2-agonist use over two weeks does not increase diurnal variation or induce tolerance during home PEF monitoring

LCLeon L. CsonkaTampere University of Applied Sciences IVIida VähätaloSeinäjoki University of Applied Sciences PIPinja Ilmarinen

Key Points

To evaluate the effects of regular short-acting β2-agonist (SABA) use over two weeks on diurnal variation and tolerance during home peak expiratory flow (PEF) monitoring.
Conducted a two-week assessment of PEF in a home setting.
Evaluated SABA usage frequency and effects.
Monitored diurnal variation and tolerance to bronchodilator effects.
No decrease in PEF observed with regular SABA use.
Diurnal variation did not increase during the two-week period.
Tolerance to bronchodilator effects was not induced.

Abstract

We conclude that regular SABA use for one or two weeks does not lead to decreased PEF, increased diurnal variation, or tolerance to its bronchodilator effects. However, such adverse effects cannot be ruled out with longer use. Regular twice-daily BDR assessment during two-week home PEF monitoring appears safe and appropriate.

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Regular short-acting β2-agonist use over two weeks does not increase diurnal variation or induce tolerance during home PEF monitoring

Key Points

Abstract

Cite This Study